Antibiotice gains new business prospects by participating in CPhI Paris

For the twelfth consecutive year, Antibiotice attended the world’s leading networking event in the pharma industry: CPhI Worldwide (Chemical and Pharmaceutical Ingredients Worldwide). CPhI Worldwide was held in Paris In early October 2014 and brought together over 2,500 exhibitors.

Antibiotice’s delegation present at the fair had overall 160 business meetings with both traditional partners from the US, Canada, UK, Denmark, as well as new partners in South Africa, Central and South America, interested in developing new partnerships concerning our products.
Accordingly, sales strategies were discussed and 7 major projects have been initiated concerning the enhancement of pharmaceutical forms and therapeutic classes existing in the company’s portfolio. All these projects will contribute to increasing export turnover by 30% in the next 3-5 years.

Following the registration procedure, sterile injectable powders will enter new markets in North and South America (Canada and Colombia), Europe (United Kingdom, the Baltic States, Ukraine) and Australia. “The successful completion of the registration of products for injection will generate an additional production estimated at around 8,000,000 million vials of penicillin for injection,” said Mihai Stoian, Business Development Manager.

Topical products (ointments, creams, gels) have generated a keen interest in markets such as the US, Canada, Mexico, UK, Germany, Spain. The competitive advantage of Antibiotice on this market segment is given by its tradition and expertise in manufacture, formulation, conducting clinical trials and drafting the documentation required for the registration of topical products. The implementation of new projects with respect to these products comes along with the achievement of a new plant for topical products topics and suppositories, which is part of the company’s business development strategy for 2014-2020.

Thus, we discussed strategies and sales have started November 7 major projects on the development of forms and therapeutic classes in the portfolio company. All these projects will help increase export turnover by 30% in the next 3-5 years.